“Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread,” the Wall Street Journal reports.

